Clinical trials
Completed Immunoglobulin Light-chain Amyloidosis trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2005 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Fondazione IRCCS Policlinico San Matteo di Pavia | 3 |
| European Myeloma Network B.V. | 2 |
| Fred Hutchinson Cancer Center | 2 |
| K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 1 |
| Millennium Pharmaceuticals, Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
| Prothena Biosciences Ltd. | 1 |
| Stichting European Myeloma Network | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immunoglobulin Light-chain Amyloidosis | 15 |
| Multiple Myeloma | 6 |
| Burkitt Lymphoma | 5 |
| Hodgkin Disease | 5 |
| Immunoblastic Lymphadenopathy | 5 |
| Intraocular Lymphoma | 5 |
| Leukemia, Biphenotypic, Acute | 5 |
| Leukemia, Hairy Cell | 5 |
| Leukemia, Large Granular Lymphocytic | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.